期刊
CLINICAL INFECTIOUS DISEASES
卷 35, 期 12, 页码 1520-1526出版社
OXFORD UNIV PRESS INC
DOI: 10.1086/344959
关键词
-
资金
- NIAID NIH HHS [AI46289] Funding Source: Medline
Highly active antiretroviral therapy (HAART) has dramatically altered the human immunodeficiency virus type 1 (HIV- 1) pandemic in the developed world. Most patients treated with HAART will maintain clinically undetectable plasma virus loads with concomitant dramatic decreases in mortality and morbidity. Nevertheless, HAART does not eradicate HIV- 1 infection on the basis of persistent low- level or cryptic viral replication and, of importance, latent provirus in resting CD4(+) T lymphocytes. New approaches are now being developed for stimulation of HAART- persistent reservoirs. Immune activation therapy (IAT) has begun to be used in attempts to stimulate the HIV- 1 latent reservoir. These studies and new approaches to activating latent virus in resting CD4(+) T cells are reviewed and critically analyzed in the present report. Development of novel IAT may lead to long- term remission or viral eradication in the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据